OAM
TPTX

Oxford Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Oxford Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,779
Closed -$405K – 2199
2019
Q3 		$405K Buy
+10,779
New +$469K 0.01% 1341

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Oxford Asset Management's TPTX Position: Q4 2019 in Review

Oxford Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2019, closing a stake of 10,779 shares — an estimated $405K sold.

Oxford Asset Management first reported a position in TPTX in Q3 2019 and held it in 1 quarter. The position peaked at $405K in Q3 2019. 120 funds tracked by Wall St. Rank hold TPTX as of Q4 2019.

  • Oxford Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Oxford Asset Management sold 10,779 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $405K.
  • Oxford Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Oxford Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $405K in Q3 2019.
  • 120 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.